AbolerIS Pharma aims to develop molecules that regulate immune responses with high selectivity and potency.
The major objective is to induce immune tolerance in clinical situations in which tissues are attacked by destructive immune responses, as it happens in autoimmunity, solid organ rejection and graft-versus-host disease during bone marrow transplantation.
Since immune responses are also essential to fight infectious agents and cancer cells, preserving these responses is essential. Furthermore, certain molecules can have tolerogenic actions, and inhibition thereof may be advantageous in the context of fighting infection or cancer. Careful evaluation of these aspects has been taken into consideration with the molecules under development by AbolerIS Pharma.
In conclusion, AbolerIS Pharma’s pipeline has an integrated and complete view of immune responses and their different manipulations.